explore -WSS

explore

author：fashion 2025-09-29 01:46:05 - browse：659

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Spinal cord stimulation reduces pain in amputees, study finds

WSS

CMS got Medicare Advantage quality rating wrong, judge rules

FDA approves Moderna’s RSV vaccine, its second licensed product

Americans' trust in science, scientist continues decline: Report

Patients' immediate access to test results puts radiologists in a bind

Roche to buy Carmot Therapeutics, developer of obesity drugs

ASCO Daily Recap: CAR

knowledge

explore

hotspot

In Memoriam: Notable people who died in 2023

Leukemia patients are helped by Syndax's new type of therapy

Activists slam private health insurers over coverage restrictions

Illumina board agrees to spin off Grail, as divestment plans proceed

Jerome Adams on the need for new antivirals for Covid

Take antibiotics after sex, CDC recommends for certain risk groups

Activists slam private health insurers over coverage restrictions

CMS should re

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare Advantage's lean provider networks lead CMS complaints

entertainment

Take antibiotics after sex, CDC recommends for certain risk groups

Medicare Advantage's lean provider networks lead CMS complaints

Stopping antidepressants leads to symptoms for 1 in 6 patients

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

An outdated Medicare rule harms dementia patients with anxiety

The most pressing bird flu mysteries scientists want answered

entertainment

knowledge

focus

knowledge